Cost of prostate image-guided radiation therapy: Results of a randomized trial - HAL Accéder directement au contenu
Article dans une revue Radiotherapy & Oncology Année : 2013

Cost of prostate image-guided radiation therapy: Results of a randomized trial

Résumé

Purpose: This cost analysis aimed to quantify the cost of IGRT in relation to IGRT frequency and modality with Cone Beam Computed Tomography (CBCT) or orthogonal electronic portal imaging with fiducial markers (EPI-FM). Material and methods: Patients undergoing IGRT for localized prostate cancer were randomized into two prostate control frequencies (daily or weekly). Costs were calculated based on the micro-costing results according to hospitals' perspectives (in Euros, 2009) and the time horizon was radiation therapy. Results: A total of 208 patients were enrolled in seven French cancer centers. A total of 6865 fractions were individually analyzed. The mean total treatment fraction duration was 21.0 min for daily CBCT and 18.3 min for daily EPI-FM. Increasing the control frequency from weekly to daily increased the mean treatment fraction duration by 7.3 min (+53%) for CBCT and 1.7 min (+10%) for EPI-FM (p <= 0.01). The mean additional cost per patient of daily controls compared with weekly controls was E679 and 187 for CBCT and EPI-FM, respectively (p < 0.0001). Conclusions: The incremental costs due to different prostate IGRT strategies are relatively moderate, suggesting that daily IGRT combined with intensity-modulated RT (IMRT) could be administered in cases of high-dose radiation delivery to the prostate
Loading...

Dates et versions

halshs-00799507, version 1 (12-03-2013)

Identifiants

Citer

Lionel Perrier, Magali Morelle, Pascal Pommier. Cost of prostate image-guided radiation therapy: Results of a randomized trial. Radiotherapy & Oncology, 2013, 106 (1), pp.50-58. ⟨10.1016/j.radonc.2012.11.011⟩. ⟨halshs-00799507⟩
57 Consultations
0 Téléchargements
Dernière date de mise à jour le 06/04/2024
comment ces indicateurs sont-ils produits

Altmetric

Partager

Gmail Facebook Twitter LinkedIn Plus